KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vir Biotechnology (VIR) Tax Provisions (2018 - 2025)

Historic Tax Provisions for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to $168000.0.

  • Vir Biotechnology's Tax Provisions fell 508.47% to $168000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $268000.0, marking a year-over-year increase of 10458.67%. This contributed to the annual value of -$1.1 million for FY2024, which is 9124.42% up from last year.
  • Per Vir Biotechnology's latest filing, its Tax Provisions stood at $168000.0 for Q3 2025, which was down 508.47% from $170000.0 recorded in Q2 2025.
  • Over the past 5 years, Vir Biotechnology's Tax Provisions peaked at $403.3 million during Q1 2022, and registered a low of -$157.2 million during Q2 2022.
  • In the last 5 years, Vir Biotechnology's Tax Provisions had a median value of $53000.0 in 2021 and averaged $12.9 million.
  • Data for Vir Biotechnology's Tax Provisions shows a peak YoY increase of 20565816.33% (in 2022) and a maximum YoY decrease of 29675660.38% (in 2022) over the last 5 years.
  • Quarter analysis of 5 years shows Vir Biotechnology's Tax Provisions stood at $20.6 million in 2021, then plummeted by 342.48% to -$50.0 million in 2022, then surged by 90.44% to -$4.8 million in 2023, then surged by 98.2% to -$86000.0 in 2024, then surged by 295.35% to $168000.0 in 2025.
  • Its Tax Provisions was $168000.0 in Q3 2025, compared to $170000.0 in Q2 2025 and $16000.0 in Q1 2025.